The 2019 European Hematology Association (EHA) Annual Meeting
We’ve just returned from the 2019 European Hematology Association (EHA) Annual Meeting where Prof Maria-Victoria Mateos (University of Salamanca - Salamanca, Spain) spoke of stand-out studies in multiple myeloma.
Prof Mateos begins by discussing the promising part 1 results of the CASSIOPEIA study looking at the addition of daratumumab to bortezomib/thalidomide/dexamethasone (D-VTd) versus VTd in transplant-eligible, newly diagnosed multiple myeloma patients. She also discusses some of the important messages from the FORTE and GEM-CESAR studies. Prof Mateos ends with the ELOQUENT-3 study in the relapse setting and also the COLUMBA study.